Drug details:
Molecular formula: C₂₇H₂₉N₉O₂

Standard name: (5R,6R)-5,6-bis[[4-(phenoxymethyl)triazol-1-yl]methyl]-4,5,6,7-tetrahydro-1H-benzimidazol-2-amine

Curated SMILES: NC1:N:C2:C(:N:1)C[C@@H](CN1:C:C(COC3:C:C:C:C:C:3):N:N:1)[C@H](CN1:C:C(COC3:C:C:C:C:C:3):N:N:1)C2

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.

Pseudomonas
Related VFcategory: Biofilm
Target: Not determined
Drug effect: Inhibits biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Huigens RW 3rd, et al., 2009. Inhibition of Acinetobacter baumannii, Staphylococcus aureus and Pseudomonas aeruginosa biofilm formation with a class of TAGE-triazole conjugates. Org Biomol Chem 7(4):794-802.